Literature DB >> 15740721

Effect of melatonin on calyculin A-induced tau hyperphosphorylation.

Xia-Chun Li1, Ze-Fen Wang, Jun-Xia Zhang, Qun Wang, Jian-Zhi Wang.   

Abstract

We have found in the present study that incubation of neuroblastma N2a with calyculin A, an inhibitor of protein phosphatase-2A (PP-2A) and protein phosphatase-1 (PP-1), reduces cell viability in a dose-dependent manner, and leads to tau hyperphosphorylation at tau-1 (Ser198/199/202) and PHF-1 (Ser396/404) epitopes. In addition to inhibit PP-2A, calyculin A treatment also results in significant activation of glycogen synthase kinase-3 (GSK-3). Calyculin A induces oxidative stress manifested by elevated level of malondialdehyde and decreased activity of superoxide dismutase. When the cells were incubated simultaneously with calyculin A and melatonin (25 microM or 50 microM), the calyculin A-induced decrease in cell viability, tau hyperphosphorylation, PP-2A/GSK-3 imbalance and oxidative stress were attenuated accordingly. These results suggest (i) that calyculin A induces tau hyperphosphorylation not only by inhibition of PP-2A, but also by activation of GSK-3 in N2a cells; (ii) that melatonin efficiently attenuates the calyculin A-induced damages through not only its antioxidant effect but also its modulation to the phosphorylation system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15740721     DOI: 10.1016/j.ejphar.2005.01.023

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  24 in total

Review 1.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

Review 2.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 3.  Promising Role of Melatonin as Neuroprotectant in Neurodegenerative Pathology.

Authors:  Neeraj Joshi; Joyshree Biswas; C Nath; Sarika Singh
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

Review 4.  Role of melatonin in neurodegenerative diseases.

Authors:  V Srinivasan; S R Pandi-Perumal; G Jm Maestroni; A I Esquifino; R Hardeland; D P Cardinali
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 5.  Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.

Authors:  C-X Gong; K Iqbal
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

6.  Effect of melatonin and melatonylvalpromide on beta-amyloid and neurofilaments in N2a cells.

Authors:  Xiao-Chuan Wang; Yin-Chun Zhang; Nithiananda Chatterjie; Inge Grundke-Iqbal; Khalid Iqbal; Jian-Zhi Wang
Journal:  Neurochem Res       Date:  2008-01-31       Impact factor: 3.996

Review 7.  The antiapoptotic activity of melatonin in neurodegenerative diseases.

Authors:  Xin Wang
Journal:  CNS Neurosci Ther       Date:  2009-10-10       Impact factor: 5.243

Review 8.  Repurposing Licensed Drugs for Use Against Alzheimer's Disease.

Authors:  Leslie C Norins
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 9.  Regulation of Melatonin and Neurotransmission in Alzheimer's Disease.

Authors:  Jaydeep Roy; Ka Chun Tsui; Jonah Ng; Man-Lung Fung; Lee Wei Lim
Journal:  Int J Mol Sci       Date:  2021-06-25       Impact factor: 5.923

Review 10.  Antioxidant therapies for Alzheimer's disease.

Authors:  Ye Feng; Xiaochuan Wang
Journal:  Oxid Med Cell Longev       Date:  2012-07-25       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.